{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:57:49Z","timestamp":1778525869787,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T00:00:00Z","timestamp":1525392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00467-018-3957-8","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T08:47:43Z","timestamp":1525423663000},"page":"1437-1442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Acquired thrombotic thrombocytopenic purpura with isolated CFHR3\/1 deletion\u2014rapid remission following complement blockade"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7472-6950","authenticated-orcid":false,"given":"Martin","family":"Bitzan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawan M.","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Bonnefoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Watfa Shahwan","family":"Al Dhaheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"V\u00e9zina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges-\u00c9tienne","family":"Rivard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,4]]},"reference":[{"key":"3957_CR1","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371:1847\u20131848","journal-title":"N Engl J Med"},{"key":"3957_CR2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","volume":"130","author":"JE Sadler","year":"2017","unstructured":"Sadler JE (2017) Pathophysiology of thrombotic thrombocytopenic purpura. Blood 130:1181\u20131188","journal-title":"Blood"},{"key":"3957_CR3","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","volume":"125","author":"PJ Lenting","year":"2015","unstructured":"Lenting PJ, Christophe OD, Denis CV (2015) von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood 125:2019\u20132028","journal-title":"Blood"},{"key":"3957_CR4","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","volume":"129","author":"BS Joly","year":"2017","unstructured":"Joly BS, Coppo P, Veyradier A (2017) Thrombotic thrombocytopenic purpura. Blood 129:2836\u20132846","journal-title":"Blood"},{"key":"3957_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.transci.2016.04.011","volume":"54","author":"P Vieira-Martins","year":"2016","unstructured":"Vieira-Martins P, El Sissy C, Bordereau P, Gruber A, Rosain J, Fremeaux-Bacchi V (2016) Defining the genetics of thrombotic microangiopathies. Transfus Apher Sci 54:212\u2013219","journal-title":"Transfus Apher Sci"},{"key":"3957_CR6","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","volume":"111","author":"M Jozsi","year":"2008","unstructured":"Jozsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C (2008) Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency. Blood 111:1512\u20131514","journal-title":"Blood"},{"key":"3957_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Fremeaux-Bacchi V, International HUS (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15\u201339","journal-title":"Pediatr Nephrol"},{"key":"3957_CR8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701\u2013711","journal-title":"Kidney Int"},{"key":"3957_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","volume":"129","author":"K Kokame","year":"2005","unstructured":"Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129:93\u2013100","journal-title":"Br J Haematol"},{"key":"3957_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/bjh.12387","volume":"162","author":"E Tsai","year":"2013","unstructured":"Tsai E, Chapin J, Laurence JC, Tsai HM (2013) Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up. Br J Haematol 162:558\u2013559","journal-title":"Br J Haematol"},{"key":"3957_CR11","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1053\/j.ajkd.2015.06.032","volume":"66","author":"C Pecoraro","year":"2015","unstructured":"Pecoraro C, Ferretti AV, Rurali E, Galbusera M, Noris M, Remuzzi G (2015) Treatment of congenital thrombotic thrombocytopenic Purpura with Eculizumab. Am J Kidney Dis 66:1067\u20131070","journal-title":"Am J Kidney Dis"},{"key":"3957_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/08998280.2017.11929576","volume":"30","author":"A Sasapu","year":"2017","unstructured":"Sasapu A, Cottler-Fox M, Motwani P (2017) Acquired thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome successfully treated with eculizumab. Proc (Bayl Univ Med Cent) 30:182\u2013183","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"3957_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1080\/07853890601097030","volume":"38","author":"GS Hageman","year":"2006","unstructured":"Hageman GS, Hancox LS, Taiber AJ, Gehrs KM, Anderson DH, Johnson LV, Radeke MJ, Kavanagh D, Richards A, Atkinson J, Meri S, Bergeron J, Zernant J, Merriam J, Gold B, Allikmets R, Dean M, Group AMDCS (2006) Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann Med 38:592\u2013604","journal-title":"Ann Med"},{"key":"3957_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1136\/jmg.2008.064766","volume":"46","author":"MA Dragon-Durey","year":"2009","unstructured":"Dragon-Durey MA, Blanc C, Marliot F, Loirat C, Blouin J, Sautes-Fridman C, Fridman WH, Fremeaux-Bacchi V (2009) The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 46:447\u2013450","journal-title":"J Med Genet"},{"key":"3957_CR15","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1111\/j.1600-6143.2012.04124.x","volume":"12","author":"D Noone","year":"2012","unstructured":"Noone D, Al-Matrafi J, Tinckam K, Zipfel PF, Herzenberg AM, Thorner PS, Pluthero FG, Kahr WH, Filler G, Hebert D, Harvey E, Licht C (2012) Antibody mediated rejection associated with complement factor h-related protein 3\/1 deficiency successfully treated with eculizumab. Am J Transplant 12:2546\u20132553","journal-title":"Am J Transplant"},{"key":"3957_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.transci.2016.04.012","volume":"54","author":"CW Teoh","year":"2016","unstructured":"Teoh CW, Riedl M, Licht C (2016) The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci 54:220\u2013231","journal-title":"Transfus Apher Sci"},{"key":"3957_CR17","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1182\/blood-2016-06-724161","volume":"128","author":"EE Page","year":"2016","unstructured":"Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN (2016) Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood 128:2175\u20132178","journal-title":"Blood"},{"key":"3957_CR18","doi-asserted-by":"publisher","first-page":"e59372","DOI":"10.1371\/journal.pone.0059372","volume":"8","author":"NA Turner","year":"2013","unstructured":"Turner NA, Moake J (2013) Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. PLoS One 8:e59372","journal-title":"PLoS One"},{"key":"3957_CR19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1538-7836.2012.04674.x","volume":"10","author":"M Reti","year":"2012","unstructured":"Reti M, Farkas P, Csuka D, Razso K, Schlammadinger A, Udvardy ML, Madach K, Domjan G, Bereczki C, Reusz GS, Szabo AJ, Prohaszka Z (2012) Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 10:791\u2013798","journal-title":"J Thromb Haemost"},{"key":"3957_CR20","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.4049\/jimmunol.1301221","volume":"191","author":"R Tati","year":"2013","unstructured":"Tati R, Kristoffersson AC, Stahl AL, Rebetz J, Wang L, Licht C, Motto D, Karpman D (2013) Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol 191:2184\u20132193","journal-title":"J Immunol"},{"key":"3957_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2013-04-495853","volume":"123","author":"J Rayes","year":"2014","unstructured":"Rayes J, Roumenina LT, Dimitrov JD, Repesse Y, Ing M, Christophe O, Jokiranta TS, Halbwachs-Mecarelli L, Borel-Derlon A, Kaveri SV, Fremeaux-Bacchi V, Lacroix-Desmazes S (2014) The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood 123:121\u2013125","journal-title":"Blood"},{"key":"3957_CR22","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1182\/blood-2014-06-585430","volume":"125","author":"S Feng","year":"2015","unstructured":"Feng S, Liang X, Kroll MH, Chung DW, Afshar-Kharghan V (2015) von Willebrand factor is a cofactor in complement regulation. Blood 125:1034\u20131037","journal-title":"Blood"},{"key":"3957_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.kint.2016.03.023","volume":"90","author":"DG Noone","year":"2016","unstructured":"Noone DG, Riedl M, Pluthero FG, Bowman ML, Liszewski MK, Lu L, Quan Y, Balgobin S, Schneppenheim R, Schneppenheim S, Budde U, James P, Atkinson JP, Palaniyar N, Kahr WH, Licht C (2016) Von Willebrand factor regulates complement on endothelial cells. Kidney Int 90:123\u2013134","journal-title":"Kidney Int"},{"key":"3957_CR24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.4049\/jimmunol.1601121","volume":"199","author":"S Bettoni","year":"2017","unstructured":"Bettoni S, Galbusera M, Gastoldi S, Donadelli R, Tentori C, Sparta G, Bresin E, Mele C, Alberti M, Tortajada A, Yebenes H, Remuzzi G, Noris M (2017) Interaction between multimeric von Willebrand factor and complement: a fresh look to the pathophysiology of microvascular thrombosis. J Immunol 199:1021\u20131040","journal-title":"J Immunol"},{"key":"3957_CR25","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","volume":"123","author":"SR Cataland","year":"2014","unstructured":"Cataland SR, Holers VM, Geyer S, Yang S, Wu HM (2014) Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 123:3733\u20133738","journal-title":"Blood"},{"key":"3957_CR26","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","volume":"157","author":"J Chapin","year":"2012","unstructured":"Chapin J, Weksler B, Magro C, Laurence J (2012) Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 157:772\u2013774","journal-title":"Br J Haematol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-3957-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-3957-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-3957-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T19:09:40Z","timestamp":1556910580000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-3957-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,4]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["3957"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-3957-8","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,4]]},"assertion":[{"value":"2 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AB and MB received honoraria from Alexion Pharmaceuticals, Inc. The remainder of the authors has no potential conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}